HepaRG cells: a fit-for-purpose system for hepatic modeling and DILI (Drug-Induced Liver Injury) prediction 

May 16, 2022

In this webinar,  Pamela Bachour El Azzi, PhD discussed the different applications of HepaRG cells: induction studies, DILI (cholestasis, steatosis) and the 3D systems.What you’ll learn: 

  • Coverage of key information about HepaRG cell model and its benefits
  • The use of HepaRG cells for CYP induction and hepatotoxicity studies
  • HepaRG cell engineering and modes of culture

All registered participants will receive access to the webinar recording. We look forward to hosting you! 

About our Speaker: Pamela Bachour El Azzi, PhD, has been Associate Professor at the Lebanese University, Beyrouth, at the Université Saint Joseph Beyrouth and at the Université Antonine Beyrouth for 7 years. She became recently Commercial Director at Wepredic group. Dr Bachour El Azzi has completed a PhD at the Rennes University, it was about characterizing bile acid transporters in HepaRG cells, investigating drug-induced cholestatic mechanisms by in vitro  methods, and more specifically deciphering chlorpromazine-induced intrahepatic cholestasis in the presence or not of an inflammatory context.

Abstract: HepaRG® cell model is a unique hepatic cell line in its ability to generate fully differentiated human hepatocytes and to express major hepatic functions for up to 4 weeks, including the main phase I and II metabolizing enzymes and hepatobiliary transporters. HepaRG® cell model has been widely used in virology, and for assessing (including for regulatory submissions) cytochrome P450 induction, deciphering xenobiotic modes of action, and studying biotransformation and genotoxic aspects. The reliability and robustness of HepaRG® cell model to predict hepatotoxicities, to mimic steatosis and steatohepatitis, and to document drug-drug interactions is reflected over the past decade by more than 800 publications. Moreover, HepaRG® cells can be genetically engineered in both proliferative and differentiated phases, for delivering ad hoc tools and unveiling gene function, regulation, and  involvement in specific cellular pathways. In addition, recent development of 3D systems of HepaRG® cells either monocultured or cocultured with non-parenchymal liver cells open new avenues for mimicking still better the in vivo liver physiology and responses to xenobiotics.

About ScitoVation: ScitoVation helps clients assess chemical compound safety using innovative science, next-generation technology, and professional expertise. ScitoVation is known for partnership, flexibility, and proven success in its work to develop safer and more effective pharmaceuticals, food ingredients, agricultural chemicals, commodity chemicals and consumer products. A spin-off of the former The CIIT and The Hammer Institutes for Chemical & Drug Safety Sciences, ScitoVation is an industry leader of New Approach Methods (NAMS) for chemical/drug discovery & development in the rapidly evolving global regulatory landscape.